Status:
COMPLETED
Impact of Prisma on Donor Site Pain
Lead Sponsor:
NYU Langone Health
Conditions:
Skin Graft Disorder
Donor Site Complication
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The purpose of this study is to assess the feasibility of evaluating the use of a composite collagen, silver-oxidized regenerated cellulose matrix compared to the standard of care dressing on donor si...
Eligibility Criteria
Inclusion
- Patient scheduled to undergo STSG for any reason
- Patient, or designated healthcare proxy, has read and signed the IRB-approved informed consent form.
Exclusion
- Active infection or history of radiation to the donor site
- Patient has a known sensitivity to Promogran Prisma™ or silver
- Elevated INR \>3.0
- Insensate at the donor site
- Chronic narcotic use (\>6 months of daily use)
Key Trial Info
Start Date :
November 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 29 2021
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04050124
Start Date
November 7 2019
End Date
November 29 2021
Last Update
April 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health
New York, New York, United States, 10016